- 作者：Ayako Suzuki ; Nakayuki Yoshimura ; Yamato Mashimo ; Maiko Numakura ; Yuko Fujimaki ; Tomomi Maeda ; Toshio Ishikawa ; Shin Fujimori ; Kazuhiro Eto
- 关键词：Dipeptidyl-peptidase 4 inhibitor ; Sitagliptin ; Concomitant drug ; Pioglitazone
- 刊名：Diabetes Metabolic Syndrome: Clinical Research Reviews
- 出版年：2013
- 出版时间：July-September, 2013
- 年：2013
- 卷：7
- 期：3
- 页码：143-147
- 全文大小：554 K
Summary
Aims
Dipeptidyl-peptidase 4 inhibitors have become one of the most popular antidiabetic drugs. However, what kind of combinations with other drugs were advantageous was not known. Here, we tried to elucidate it in a real-life clinical setting.Methods
We retrospectively studied efficacies of sitagliptin in 87 Japanese patients with type 2 diabetes mellitus for 52 weeks. We divided subjects into excellent, effective and unresponsive subgroups according to glycemic responses to sitagliptin.
Results
In the excellent and effective groups the minimum HbA1c values were attained at 16 weeks while HbA1c levels in the unresponsive group kept increasing during the study period. There was a significant difference in the baseline HbA1c values between the excellent and unresponsive groups (p = 0.02). Interestingly, the mean doses of pioglitazone were highest in the excellent group and lowest in the unresponsive group (p = 0.02). When we compared the effective and unresponsive groups, the mean doses of sulfonylureas were constantly higher in the effective group than in the unresponsive group (p = 0.05).
Conclusions
These data suggest that the baseline HbA1c value can be a factor that predicts the extent of HbA1c reduction and reveal a possibility that the concomitant use of pioglitazone augments glycemic responsiveness to sitagliptin.